Maarten Frijlink

Director de Operaciones en Xenikos BV .

Health Technology

Perfil

Maarten Frijlink is currently the Chief Operating Officer at Xenikos BV since 2015.
Prior to this, he worked as the Director of Business Development at Kiadis Pharma BV.

Cargos activos de Maarten Frijlink

Empresas	Cargo	Inicio
Xenikos BV Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.	Director de Operaciones	01/01/2015

Todos los cargos activos de Maarten Frijlink

Antiguos cargos conocidos de Maarten Frijlink.

Empresas	Cargo	Fin
Kiadis Pharma BV Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Maarten Frijlink.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Maarten Frijlink.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Kiadis Pharma BV Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.	Health Technology
Xenikos BV Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.	Health Technology